Nexalin Technology (NXL) shares were down 15% Friday after the medical device company filed a preliminary prospectus for the potential sale of nearly 2.8 million shares available to Maxim Partners by exercising warrants issued to the private equity firm during the company's initial public offering in September 2022.
Maxim can exercise warrants to buy nearly 2.7 million shares at $4.15 apiece anytime within three years of their 2022 issue. Nexalin's stock topped the exercise price for the first time ever on Nov. 15 and traded as high as $4.18 per share as recently as Dec. 13 but closed Thursday at $3.06 and were extending their retreat on Friday.
Nexalin would receive around $11 million in gross proceeds if Maxim exercised all of its available warrants, and is not due to receive any proceeds from the sale of any shares by Maxim, according to the company's prospectus.
Price: 2.60, Change: -0.46, Percent Change: -15.00
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。